Nuwiq, Human cell line recombinant human factor VIII (Human-cl rhFVIII) 3000 IU powder and solvent for solution for injection. Vial of powder and prefilled WFI syringe

Kraj: Australia

Język: angielski

Źródło: Department of Health (Therapeutic Goods Administration)

Składnik aktywny:

simoctocog alfa, Quantity: 3000 IU

Dostępny od:

Octapharma Australia Pty Ltd

Forma farmaceutyczna:

Injection, powder for

Skład:

Excipient Ingredients: poloxamer; arginine hydrochloride; sucrose; sodium chloride; sodium citrate dihydrate; calcium chloride dihydrate

Droga podania:

Intravenous

Sztuk w opakowaniu:

1 vial

Typ recepty:

exempt from scheduling - Appendix A; prescription medicine

Wskazania:

Treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia A (congenital factor VIII deficiency). Nuwiq does not contain von Willebrand Factor and is thus not indicated to treat von Willebrand?s Disease.

Podsumowanie produktu:

Visual Identification: Nuwiq - white to off-white lyophilised powder,WFI - clear, colourless liquid; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Status autoryzacji:

Registered

Data autoryzacji:

2020-11-12